Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-{2-[(4'-cyano-1,1'-biphenyl-4-yloxy]ethyl}-N'-hydroxy-N-methylurea is a synthetic small molecule with the molecular formula C17H17N3O3 and a molecular weight of approximately 311.33 g/mol[1][2][5]. It is classified as an experimental compound and has not been approved for clinical use in any jurisdiction[3][4]. The compound is structurally related to biphenyl derivatives and contains both cyano and hydroxyurea functional groups. It has been studied primarily as a research tool rather than as a therapeutic agent. Structural data indicate it can act as an inhibitor of matrix metalloproteinase enzymes (notably MMP8), based on its co-crystallization with MMP8 in protein databanks[7]. No information about its mechanism of action in humans or animals, clinical indications, or therapeutic applications is available.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-{2-[(4'-cyano-1,1'-biphenyl-4-yl)oxy]ethyl}-N'-hydroxy-N-methylurea.